Fentanyl Taifun is a fast-acting Fentanyl formulation delivered using the company's Taifun dry powder inhaler platform. The patients experienced significant pain relief in 95% of the pain episodes treated. The estimate of the median time to significant pain relief was seven minutes. Based on the interim adverse event data, Fentanyl Taifun suggested high tolerance in opioid tolerant cancer patients.
Dr Halvor Jaeger, CEO of LAB International, said: “In order to maintain and strengthen our leading position among inhaled fentanyl developers, we have filed a new patent application on the product, making it more difficult for followers to imitate our unique clinical profile.”
Chronic pain associated with advanced cancer is commonly treated with strong opioid analgesics, such as fentanyl. Breakthrough pain episodes are sudden and intense flares of pain that “break through” a long-acting continuous treatment, such as a transdermal patch or a slow release tablet. Breakthrough pain episodes are common in cancer patients, often occurring several times a day.